Priyanka S. Sutar, Manojkumar K. Munde, Vijaya S. Vichare, Nilesh S. Kulkarni
Priyanka S. Sutar*, Manojkumar K. Munde, Vijaya S. Vichare, Nilesh S. Kulkarni
Modern College of Pharmacy, Pune, Maharashtra, India. Affiliated to Savitribai Phule, Pune University, Pune.
Volume - 12,
Issue - 2,
Year - 2022
The degradation of new drug ingredients and drug products in more severe settings than accelerated conditions is referred to as forced degradation research. Forced degradation experiments were carried out to demonstrate the specificity of stability-indicating methodologies, providing insight into degradation pathways and drug degradation products, and assisting in the understanding of degradation product structures., identifying degradation products that could be spontaneously generated during storage and use of drugs and to facilitate improvement in manufacturing process and formulation corresponding with accelerated stability studies Statins, a type of lipid-lowering medication, are the most commonly prescribed and are an example of an unstable drug. In the presence of high temperatures and humidity, statins are susceptible to hydrolysis. As a result, the review discusses various studies of statin drug forced degradation studies. To describe the drug's intrinsic stability, the terms atorvastatin, Fluvastatin, pitavastatin, ruvastatin, simvastatin, and pravastatin are used. assist the selection of formulations and packaging as well as proper storage conditions.
Cite this article:
Priyanka S. Sutar, Manojkumar K. Munde, Vijaya S. Vichare, Nilesh S. Kulkarni. Review on Forced Degradation Study of Statins. Asian Journal of Pharmaceutical Analysis. 2022; 12(2):135-1. doi: 10.52711/2231-5675.2022.00024
Priyanka S. Sutar, Manojkumar K. Munde, Vijaya S. Vichare, Nilesh S. Kulkarni. Review on Forced Degradation Study of Statins. Asian Journal of Pharmaceutical Analysis. 2022; 12(2):135-1. doi: 10.52711/2231-5675.2022.00024 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2022-12-2-12
1. Singh S et al. Forced degradation studies to assess the stability of drugs and products. Trends Anal Chem 2013; 49:1-41.
2. ICH Expert Working Group. ICH guideline Q1A (R2): stability testing of new drug substances and products. Int Conf Harmon; 2003. p. 24.
3. Blesse M et al. Development of forced degradation and Stability indicating studies of drugs-a review. J Pharm Anal 2014; 4:159-65.
4. Jenke DR. Chromatographic method validation: a review of current practices and procedures. II. Guidelines for primary validation parameters. J Liq Chromatogram 1996; 19:737–57.
5. Ferenczi Fodor K et al. Impurity profiling of pharmaceuticals by thin-layer chromatography. J Chromatogram A 2011; 1218:2722-31.
6. Baksh M et al. Development of validated stability- indicating assay methods–critical review. J Pharm Biomed Anal 2002; 28:1011–40.
7. Davidson MH et al. Rosuvastatin: a highly efficacious statin for the treatment of dyslipidemia. Expert Opin Investig Drugs 2002; 11:125-41.
8. Petyaev et al. Improvement of hepatic bioavailability as a new step for the future of statin. Arch Med Sci 2015; 11:406-10.
9. Schachter M et al. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2004; 19:117-25.
10. Sanjaymitra PVSS et al. Dissolution and solubility enhancement strategies: current and novel prospectives. J Crit Rev 2018; 5:1-10.
11. Gupta D et al. Improvement of efficacy and safety profile of simvastatin in comparison to the reference product (Zocor tablets) using nanoparticulate formulation approach. Int J Curr Pharm Res 2016; 8:39-47.
12. Reddy KVR et al. The role of the needle in the formulation of pH-sensitive swellable microbeads prepared with hydrophilic polymers for atorvastatin and their characterization studies. Int J Appl Pharm 2017; 9:20-30.
13. Dayyih W et al. Liquorice beverage effect on the pharmacokinetic parameters of atorvastatin, simvastatin, and lovastatin by liquid chromatography-mass spectroscopy/mass spectroscopy. Asian J Pharm Clin Res 2016; 9:174-9.
14. Alvarez Lueje A et al. Stability study of simvastatin under hydrolytic conditions assessed by liquid chromatography. J AOAC Int 2005; 88:1631-6.
15. Jemal m et al. Direct-injection LC–MS–MS method for high-throughput simultaneous quantitation of simvastatin and simvastatin acid in human plasma. J Pharm Biomed Anal 2000; 23:323-40.
16. Shah RP et al. Liquid chromatography/mass spectrometric studies on atorvastatin and its stress degradation products. Rapid Commun Mass Spectrom 2008; 22:613-22.
17. Kadav AA et al. Stability-indicating UPLC method for simultaneous determination of atorvastatin, fenofibrate, and their degradationproducts in tablets. J Pharm Biomed Anal 2008; 48:120-6.
18. Vora DN et al. Validated ultra HPLC method for the simultaneous determination of atorvastatin, aspirin, and their degradation products in capsules. J Liq Chromatogr Relate Technol 2008; 31:2821-37.
19. Kumar KK et al. A validated stability indicating RP-UPLC method for atorvastatin calcium. Am J Anal Chem 2012; 3:392-9?
20. Vukkum P et al. Stress degradation behavior of atorvastatin calcium and development of a suitable stability-indicating LC method for the determination of atorvastatin, its related impurities, and its degradation products. Sci Pharm 2013; 81:93-114.
21. Gite S et al. Validation of RP-HPLC method and stress degradation for the combination of metformin HCl, atorvastatin calcium, and glimepiride: application to nanoparticles. J Chromatogram Sci 2015; 53:1654-62.
22. Singh S et al. Stability-indicating RP-HPLC method for estimation of atorvastatin calcium in the solid dosage form. Bull Pharm Res 2014; 4:9-13.
23. sathiyasundar KVR et al. new stability indicating assay method by liquid chromatographic separation of aspirin, atorvastatin, and clopidogrel in the pharmaceutical dosage form. Indo Am J Pharm Res 2014; 4:5919-27.
24. Oliveira et al. Degradation kinetics of atorvastatin under stress conditions and chemical analysis by HPLC. 2013; 18:1447-56.
25. Lakka NS et al. Development and validation of a stability-indicating RP-HPLC for the simultaneous determination of atorvastatin calcium and simvastatin in pharmaceutical solid dosage forms. Int J Res Pharm Sci 2011; 2:608-15.
26. Aiyalu R et al. HPTLC method development, validation, and stress degradation studies for atorvastatin and ezetimibe in the multicomponent tablet dosage form. Med Chem Res 2012; 21:1297-301.
27. Goel A et al. Development and validation of stability-indicating assay method by UPLC for a fixed dose combination of atorvastatin and ezetimibe. J Chromatogram Sci 2013; 51:222-8.
28. S Naidu et al. A validated stability indicating RP-HPLC method for the simultaneous determination of atorvastatin calcium and ezetimibe hydrochloride in bulk and tablet dosage form. Int J Pharm Pharm Sci 2016; 8:370-7.
29. Akabari AH et al. Development and validation of stability indicating RP-HPLC method for estimation of Fluvastatin sodium in bulk and capsule dosage form. Eurasian J Anal Chem 2017; 12:87-105.
30. Gomes FP et al. Development and validation of stability- indicating HPLC methods for quantitative determination of pravastatin, Fluvastatin, atorvastatin, and rosuvastatin in pharmaceuticals. Anal Lett 2009; 42:1784-804.
31. Akabari AH et al. Kinetic determinations of pitavastatin calcium by a stability indicating HPTLC method. J Liq Chromatogram Relate Technol 2015; 38:521-31.
32. Damle MC et al. Stability-indicating HPTLC method for the estimation of pitavastatin calcium in the presence of acid-induced degradation product. Int J Chemtech Res 2014; 6:2824-33.
33. HJ Panchal BNS et al. Stability-indicating liquid chromatographic method for analysis of pitavastatin calcium in tablet dosage forms. Acta Chromatogram 2011; 23:81-94.
34. Sujatha K et al. A new validated stability- indicating RP-HPLC method for the estimation of pitavastatin in tablet dosage forms. Int J Pharm Anal Res 2014; 3:67-73.
35. Onal A et al. Development of a selective LC method for the determination of pravastatin sodium. Chromatographic 2006; 64:157-62.
36. Athota RV et al. Stability indicating HPLC method for the simultaneous quantification of aspirin and pravastatin in bulk and tablets: method development and validation. J Appl Pharm Sci 2017; 7:48-56.
37. An Ahmad et al. A validated stability-indicating method for simultaneous analysis of mevastatin and pravastatin in fermentation broth during bioconversion by Actinomadura macra. Acta Chromatogram 2011; 23:121-31.
38. Reddy GR et al. Development of a stability- indicating stereoselective method for quantification of the enantiomer in the drug substance and pharmaceutical dosage form of rosuvastatin calcium by an enhanced approach. Sci Pharm 2015; 83:279-96.
39. Venkat G et al. Development and validation of a stability-indicating UPLC method for rosuvastatin and its related impurities in pharmaceutical dosage forms. Quim Nov 2011; 34:250-5.
40. Mostafa NM et al. Selective chromatographic methods for the determination of rosuvastatin calcium in the presence of its acid degradation. J Liq Chromatogram Relat Technol 2014; 37:2182-96.
41. Badawy AMRM et al. Stability-indicating PLS and PCR chemometric methods for the determination of rosuvastatin in presence of its two oxidative degradation products. Int J Pharm Pharm Sci 2011; 3:232-7.
42. Trivedi HK et.al. Development and validation of a stability-indicating RP-UPLC method for determination of rosuvastatin and related substances in the pharmaceutical dosage form. Sci Pharm 2012; 80:393-406.
43. Shah RP et al. LC-MS/TOF, LC-MS, on-line H/D exchange and LC-NMR studies on rosuvastatin degradation and in silico determination of toxicity of its degradation products: a comprehensive approach during drug development. Anal Bio anal Chem 2013; 405:3215-31.
44. Ashfaq M et al. Simultaneous estimation of rosuvastatin and amlodipine in pharmaceutical formulations using stability indicating HPLC method. Brazilian J Pharm Sci 2014; 50:629-36.
45. Mukthinuthalapati MA et al Stability indicating liquid chromatographic method for the simultaneous determination of rosuvastatin and ezetimibe in pharmaceutical formulations. Adv Pharm Bull 2014; 4:405-11.
46. Belal et al. Stability indicating TLC method for the determination of rosuvastatin and identification of some degradation products using electrospray ionization mass spectrometry. J Liq Chromatogram Relat Technol 2014; 37:1114-32.
47. Kapuganti ANK et al, Srinivas K, et al. Development and validation of stability indicating RP-HPLC method for simultaneous estimation of ramipril, aspirin, and simvastatin in bulk and pharmaceutical dosage form. Asian J Biomed Pharm Sci 2016; 6:14-20.
48. El Karbane M et al. Development and validation of a reversed-phase HPLC method for simultaneous analysis of butylhydroxyanisol, simvastatin, and its impurities in tablet dosage forms. Ann Pharm Fr 2014:72:244-55.
49. Kumar P et al. Stability indicating RP-HPLC method development for determination of simvastatin in dosage forms. World J Pharm Sci 2014; 3:1189-205.
50. Rao et al. Stability-indicating liquid chromatographic method for the simultaneous determination of ascorbic acid, citric acid, butylated hydroxyanisole, simvastatin, and related compounds in the pharmaceutical solid dosage form. Int J Anal Pharm Biomed Sci 2014; 3:1-10.
51. Devu S et al. Chromatography development and validation of stability indicating RP-UPLC method for simultaneous determination in fixed dose combination of ezetimibe and simvastatin. J Chromat Separation Techniq 2012; 3:1-7.
52. Gomes FP et al. UV-derivative spectrophotometric and stability-indicating high-performance liquid chromatographic methods for determination of simvastatin in tablets. Latt Am J Pharm 2009; 28:261-9.
53. Silva TD et al. Development and validation of a simple and fast HPLC method for determination of lovastatin, pravastatin, and simvastatin. J Chromatogr Sci 2012; 50:831-8.
54. Ghodke SS et al. Stability indicating RP-HPLC method for simvastatin and sitaglipin phosphate with degradation studies in marketed pharmaceutical hypo-cholesterol and antidiabetic tablets. Int J Pharm Chem Biol Sci 2018; 8:99-109.
55. Chavhan V et al. Stability indicating UV spectrophotometric method development and validation of simvastatin in bulk and tablet dosage form. J Appl Pharm 2014; 6:235-46.
56. Sawant S et al. A validated stability indicating RP-HPLC method for simvastatin, identification and characterization of forced degradation products of simvastatin using LC-ESI- MS/MS. Adv Anal Chem 2015;5:8-16.
57. Malenovic A et al. Forced degradation studies of simvastatin using microemulsion liquid chromatography. J Liq Chromatogr Relat Technol 2010; 33:536-47.
58. Nalaiya J, Sagineedu SRAO, Rajasingam R, Kassim Z, Pichika MRAO.
59. 58A stability-indicating RP-HPLC method for simultaneous determination of simvastatin and niacin in a combined dosage form. Int J Pharm Pharm Sci 2015; 7:262-8
60. Shubhangi V. Sutar et al. Stability Indicating Forced Degradation Studies. Research J. Pharm. and Tech 2019; 12(1): 429-433 doi: 10.5958/0974-360X.2019.00078.7.
61. M. Boobalan et al. Stability Indicating Forced Degradation Studies to Assess Degradation behaviour of Chlordiazepoxide and Amitriptyline Hydrochloride in Pharmaceutical Dosage Form by RP-HPLC. Research J. Pharm. and Tech. 2020; 13(1): 313-318. doi: 10.5958/0974-360X.2020.00063.3
62. M. Sumithra et al. Analytical method development and validation of ambroxol hydrochloride by UV spectroscopy and forced degradation study and detection of stability. Research J. Pharm. and Tech. 2016; 9(7):794-800 doi: 10.5958/0974-360X.2016.00152.9.
63. Tentu Nageswara Rao et al. Forced Degradation Study for Tolterodine by HPLC with PDA Detection. Asian J. Pharm. Ana. 2019; 9(2):77-81. doi: 10.5958/2231-5675.2019.00015.2
64. Brummer H et al. How to approach a forced degradation study. Life science technical bulletin issue. 2011: 3.
65. Deshmukh SR. et.al, Impurity profiles in pharmaceutical substances- a comprehensive: a review. Int J Pharm Bio Sci. 1(4); 2011: 382-9
66. International Conference on Harmonization, “ICH Q1A(R2): Stability Testing of New Drug Substances and Products,” Step 5 (2003)
67. ICH Harmonized Tripartite Guideline Q1B: Stability Testing: Photostability Testing of New Drug Substances and Products
68. Klick S et al. Towards a Generic Approach for Stress Testing of Drug Substances and Drug Products. Pharm. Technol. 29(2); 2005: 48-66.
69. Alsante KM et al. A Stress Testing Benchmarking Study. Pharm. Technol. 27 (2); 2003: 60–72